eligibility_summary
Inclusion: Age 5–75, R/R cHL after frontline, PET-avid, prior checkpoint >6 mo, ECOG 0–2 (peds K/L ≥50), fit for HD chemo/ASCT, ANC ≥1000 (≥500 if marrow/hypersplenism), platelets ≥75k (≥25k), hepatic enzymes/bilirubin within limits, renal OK (adult GFR ≥50, peds per age), LVEF ≥50% (SF ≥27% if <18), controlled HIV/HBV/HCV, treated brain mets/other cancers OK, cardiac ≤NYHA 2B. Exclude pregnancy/breastfeeding, contraception, pneumonitis/ILD, active autoimmune or systemic immunosuppression (except replacement).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Randomized Phase III (withdrawn) in relapsed/refractory classical Hodgkin lymphoma compares salvage chemotherapy alone vs pembrolizumab plus chemotherapy, followed by high‑dose chemo and autologous stem cell transplant (optional brentuximab vedotin maintenance). Drugs/MOA: pembrolizumab—anti‑PD‑1 monoclonal antibody (immune checkpoint inhibitor) restoring T‑cell antitumor function, ifosfamide and bendamustine—alkylating agents (DNA crosslinking/strand breaks), carboplatin—platinum DNA crosslinker, etoposide and pegylated liposomal doxorubicin—topoisomerase II–targeting cytotoxics (doxorubicin also intercalates DNA), gemcitabine—antimetabolite nucleoside analog inhibiting DNA synthesis, vinorelbine—vinca alkaloid inhibiting microtubules, brentuximab vedotin—anti‑CD30 antibody–drug conjugate delivering MMAE (microtubule disruption). Targets: PD‑1/PD‑L1 pathway on T cells, CD30 on Reed–Sternberg cells, DNA replication/repair and microtubules in proliferating lymphoma cells.